Sanofi (SNY) Reports Q3 EPS of EUR1.25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Sanofi - Q3 2015 Results
October 29, 2015 3:53 AM EDTPARIS, October 29, 2015 /PRNewswire/ --
Sanofi, a global and diversified healthcare leader, reports results for the third quarter of 2015. Jérôme Contamine, Chief Financial Officer of Sanofi, comments on the Group's Q3 results.
Watch video interview and read... More
Sanofi grew sales and business EPS(1) in Q3 2015
October 29, 2015 2:47 AM EDTPARIS, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Group sales(2) increased 3.4% (up 9.2% on a reported basis) to 9,591 million Diabetes sales decreased 6.6%, as a result of lower U.S. sales of Lantus® Genzyme sales (up 32.7%) showed strong momentum driven by Multiple Sclerosis products Vaccines sales were up 5.5% mainly driven by Emerging Markets(3) Animal Health delivered another strong performance (up 9.3%) driven by NexGard® Emerging Markets sales increased by 11.4% Steady financial performance taking into account higher investments in new products
Operating expenses were 3,816m, up 7.5% at CER Business net income grew 5.0% at CER (up 8.3% on a reported basis) to 2,096 million Business EPS increased 6.1%... More
